SG183543A1 - Food comprising glucomannan, xanthan gum and alginate for the treatment of metabolic disorders - Google Patents

Food comprising glucomannan, xanthan gum and alginate for the treatment of metabolic disorders Download PDF

Info

Publication number
SG183543A1
SG183543A1 SG2012064176A SG2012064176A SG183543A1 SG 183543 A1 SG183543 A1 SG 183543A1 SG 2012064176 A SG2012064176 A SG 2012064176A SG 2012064176 A SG2012064176 A SG 2012064176A SG 183543 A1 SG183543 A1 SG 183543A1
Authority
SG
Singapore
Prior art keywords
vfc
alginate
xanthan gum
glucomannan
study
Prior art date
Application number
SG2012064176A
Other languages
English (en)
Inventor
Roland J Gahler
Michael Lyon
Simon Wood
Christopher John Lawson
Original Assignee
Inovobiologic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inovobiologic Inc filed Critical Inovobiologic Inc
Publication of SG183543A1 publication Critical patent/SG183543A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21Addition of substantially indigestible substances, e.g. dietary fibres
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/244Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from corms, tubers or roots, e.g. glucomannan
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/256Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seaweeds, e.g. alginates, agar or carrageenan
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/269Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
    • A23L29/27Xanthan not combined with other microbial gums
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/723Xanthans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734Alginic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/328Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG2012064176A 2010-03-10 2011-03-10 Food comprising glucomannan, xanthan gum and alginate for the treatment of metabolic disorders SG183543A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31263010P 2010-03-10 2010-03-10
US35765810P 2010-06-23 2010-06-23
PCT/CA2011/000260 WO2011109900A1 (en) 2010-03-10 2011-03-10 Food comprising glucomannan, xanthan gum and alginate for the treatment of metabolic disorders

Publications (1)

Publication Number Publication Date
SG183543A1 true SG183543A1 (en) 2012-10-30

Family

ID=44560211

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2012064176A SG183543A1 (en) 2010-03-10 2011-03-10 Food comprising glucomannan, xanthan gum and alginate for the treatment of metabolic disorders

Country Status (12)

Country Link
US (1) US20110223192A1 (enExample)
EP (1) EP2544696B1 (enExample)
JP (3) JP2013525269A (enExample)
KR (1) KR20130039726A (enExample)
CN (1) CN102892421A (enExample)
AU (2) AU2011226708B2 (enExample)
BR (1) BR112012022799B1 (enExample)
CA (2) CA2791418C (enExample)
NZ (1) NZ602249A (enExample)
RU (1) RU2553348C2 (enExample)
SG (1) SG183543A1 (enExample)
WO (1) WO2011109900A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010039734A1 (de) * 2010-08-25 2012-03-01 Bayer Materialscience Aktiengesellschaft Katalysator und Verfahren zur Herstellung von Chlor durch Gasphasenoxidation
GB201110672D0 (en) * 2011-06-23 2011-08-10 M I Drilling Fluids Uk Ltd Wellbore fluid
TWI469785B (zh) * 2012-04-25 2015-01-21 Inovobiologic Inc 用於治療代謝性疾病之膳食纖維組成物
RU2672594C2 (ru) * 2013-07-01 2018-11-16 Юниверсити Оф Саутерн Калифорния Состояние воздержания от пищи в качестве диетического лечения диабета
CN104277130A (zh) * 2013-07-02 2015-01-14 中国科学院上海药物研究所 一种硫酸酯化聚古洛糖酸多糖或其可药用盐及其制备方法和用途
CN103604884B (zh) * 2013-11-21 2015-10-28 南京工业大学 一种检测海藻生物质内还原性糖类物质的方法
EP3082466B1 (en) * 2013-12-18 2019-08-21 Thylabisco AB Use of thylakoids to reduce the urge for palatable food
KR20160001935A (ko) 2014-06-30 2016-01-07 원광대학교산학협력단 블랙 커런트 추출물을 유효성분으로 함유하는 대사증후군의 예방, 개선 또는 치료를 위한 조성물
CN104391049B (zh) * 2014-09-20 2017-03-22 鄂尔多斯市中轩生化股份有限公司 黄原胶微量溶剂残留量的检测方法
SMT202300091T1 (it) * 2014-11-26 2023-05-12 Omega Pharma Innovation And Dev Nv Composizione di fibre dietetica
ES2857557T3 (es) * 2015-01-26 2021-09-29 Kaleido Biosciences Inc Compuestos terapéuticos de glicano y métodos relacionados de los mismos
CA3224535A1 (en) * 2016-01-12 2017-07-20 University Of Southern California Use of long-term fasting mimicking as dietary treatment for multiple myeloma and other cancers
US10485253B2 (en) 2017-08-21 2019-11-26 Mustapha Benmoussa Method of microalgal biomass processing for high-value chemicals production, the resulting composition of butyrogenic algal slowly fermenting dietary fiber, and a way to improve colon health using a slowly fermenting butyrogenic algal dietary fiber
EP3827027A4 (en) 2018-07-23 2022-04-27 Nutragenom, LLC COMPOSITION AND METHODS FOR GENERATE AND MAINTAIN MOLECULAR HYDROGEN (H2) IN AQUEOUS SYSTEMS
CN110412157A (zh) * 2019-07-17 2019-11-05 广州金评检测研究院有限公司 一种烟酰胺原料中烟酸的测定方法
JP7412759B2 (ja) * 2020-04-16 2024-01-15 松谷化学工業株式会社 水溶性食物繊維のエネルギー量の簡便な測定方法
CN112933105A (zh) * 2021-02-10 2021-06-11 浙江工业大学 甘露葡萄糖醛酸多(寡)糖及硫酸化衍生物在制备治疗非酒精性脂肪肝药物中的应用
CN112782321A (zh) * 2021-03-09 2021-05-11 上海市质量监督检验技术研究院 一种快速检测纺织品中维生素e含量的测定方法
CN117665192A (zh) * 2023-06-30 2024-03-08 辰欣药业股份有限公司 一种特殊医学用途全营养配方乳剂食品中钾、钙、钠、镁的测定方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0683118B2 (ja) * 1988-01-19 1994-10-19 日本電気株式会社 直流終端回路
JPH02245148A (ja) * 1989-03-17 1990-09-28 Unie Koroido Kk グルコマンナンの凝固方法及びこれに用いる組成物
US5460957A (en) * 1992-04-28 1995-10-24 Maruha Corporation Calcium alginate oligosaccharide and method for producing the same from potassium or sodium alginate
US20020044988A1 (en) * 2000-08-22 2002-04-18 Fuchs Eileen C. Nutritional composition and method for improving protein deposition
GB0406013D0 (en) * 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
US8062686B2 (en) * 2005-04-12 2011-11-22 InovoBiologics, Inc. Dietary supplement, and methods of use
US8597709B2 (en) * 2005-04-12 2013-12-03 Inovobiologic Inc. Dietary supplement and methods of use

Also Published As

Publication number Publication date
BR112012022799A2 (pt) 2021-03-23
AU2014213536A1 (en) 2014-09-04
US20110223192A1 (en) 2011-09-15
KR20130039726A (ko) 2013-04-22
JP2013525269A (ja) 2013-06-20
JP2017074072A (ja) 2017-04-20
AU2011226708B2 (en) 2015-04-02
CA2791418A1 (en) 2011-09-15
JP2015083604A (ja) 2015-04-30
CA2791418C (en) 2016-07-05
NZ602249A (en) 2014-10-31
AU2011226708A1 (en) 2012-09-27
EP2544696B1 (en) 2019-05-22
CN102892421A (zh) 2013-01-23
WO2011109900A1 (en) 2011-09-15
RU2012142237A (ru) 2014-04-20
BR112012022799B1 (pt) 2021-11-30
RU2553348C2 (ru) 2015-06-10
EP2544696A1 (en) 2013-01-16
EP2544696A4 (en) 2013-08-21
CA2859055A1 (en) 2011-09-15

Similar Documents

Publication Publication Date Title
AU2011226708B2 (en) Food comprising glucomannan, xanthan gum and alginate for the treatment of metabolic disorders
Singh et al. Review on bile acids: effects of the gut microbiome, interactions with dietary fiber, and alterations in the bioaccessibility of bioactive compounds
Dai et al. Classification and regulatory perspectives of dietary fiber
Rose et al. Influence of dietary fiber on inflammatory bowel disease and colon cancer: importance of fermentation pattern
Liu et al. The physicochemical properties, in vitro binding capacities and in vivo hypocholesterolemic activity of soluble dietary fiber extracted from soy hulls
Roberfroid Dietary fiber, inulin, and oligofructose: a review comparing their physiological effects
Panahi et al. β-Glucan from two sources of oat concentrates affect postprandial glycemia in relation to the level of viscosity
Coudray et al. Effect of soluble or partly soluble dietary fibres supplementation on absorption and balance of calcium, magnesium, iron and zinc in healthy young men
Tamargo et al. Intake of soluble fibre from chia seed reduces bioaccessibility of lipids, cholesterol and glucose in the dynamic gastrointestinal model simgi®
Blackwood et al. Dietary fibre, physicochemical properties and their relationship to health
Houghton et al. Biological activity of alginate and its effect on pancreatic lipase inhibition as a potential treatment for obesity
Smith et al. Butyric acid from the diet: actions at the level of gene expression
Marounek et al. Effect of pectin and amidated pectin on cholesterol homeostasis and cecal metabolism in rats fed a high-cholesterol diet.
Belghith et al. Hypolipidemic effect of diet supplementation with bacterial levan in cholesterol-fed rats
JP2014530856A (ja) 満腹を誘導する方法および組成物
de Almeida Jackix et al. Taioba (Xanthosoma sagittifolium) leaves: nutrient composition and physiological effects on healthy rats
Méndez-Albiñana et al. Structure and properties of citrus pectin as influencing factors of biomarkers of metabolic syndrome in rats fed with a high-fat diet
Liu et al. Effects of pectins and sugars on β-carotene bioaccessibility in an in vitro simulated digestion model
CN101622032A (zh) 预防或治疗代谢综合征的方法
Takahama et al. Inhibition of buckwheat starch digestion by the formation of starch/bile salt complexes: possibility of its occurrence in the intestine
TWI630875B (zh) 用於延遲代謝症候群之發作及/或降低代謝症候群之嚴重性的方法
Thibault et al. Sugar beet fiber: production, composition, physicochemical properties, physiological effects, safety, and food applications
Parolini Effects of fibers and gut microbiota on low-grade inflammatory human disease
Yamatoya et al. Effects of xyloglucan on lipid metabolism
Srinivasan Cluster beans